Pangu
Contact
Clinical Trials
Patients

Skip to content

Company
Our Science
R&D
Patients
Careers
- Working at aTyr
- Career Opportunities
Investors and Media

© 2007 - 2024 aTyr Pharma. Legal Privacy Policy

Exposure-Efficacy Analysis Supports Proof of Concept for Efzofitimod in Pulmonary Sarcoidosis

American Thoracic Society, 2023

« Efzofitimod, a Novel Immunomodulator for Pulmonary Sarcoidosis, Modulates Patient Inflammatory Responses Through Myeloid Cells

EFZO-FIT™: A Phase 3 Study of Efzofitimod, a Novel Immunomodulator for the Treatment of Pulmonary Sarcoidosis »

© 2007 - 2024 aTyr Pharma. Legal Privacy Policy

By continuing to browse this site, you agree to our use of cookies.

MENU

Company
Our Science
R&D
Patients
Careers
- Career Opportunities
- Working at aTyr
Investors and Media
Privacy Policy